{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:15:06Z","timestamp":1792145706699,"version":"4.4.0"},"reference-count":102,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"DOI":"10.3389\/fnagi.2017.00068","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T23:51:58Z","timestamp":1490140318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":429,"title":["ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?"],"prefix":"10.3389","volume":"9","author":[{"given":"Dmitry","family":"Petrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Moussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"B2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12017-008-8053-y","article-title":"Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.","volume":"10","author":"Adhihetty","year":"2008","journal-title":"Neuromolecular Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1474-4422(10)70068-5","article-title":"Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.","volume":"9","author":"Aggarwal","year":"2010","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00002826-199512000-00004","article-title":"A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group.","volume":"18","author":"ALS CNTF Treatment Study Group","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1212\/WNL.46.5.1244","article-title":"A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis.","volume":"46","author":"ALS CNTF Treatment Study Group","year":"1996","journal-title":"Neurology"},{"key":"B6","author":"ARISLA (Fondazione Italiana de Ricerca Per La Sclerosi Laterale)","year":"2014","journal-title":"ALS Clinical Trials List."},{"key":"B7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/10715760290021315","article-title":"Coenzyme Q10 as a possible treatment for neurodegenerative diseases.","volume":"36","author":"Beal","year":"2002","journal-title":"Free Radic. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","article-title":"A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we Learned in the Last Decade?","volume":"17","author":"Bellingham","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-016-1587-4","article-title":"ALS and FTD: an epigenetic perspective.","volume":"132","author":"Belzil","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis.","volume":"249","author":"Bensimon","year":"2002","journal-title":"J. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group.","volume":"330","author":"Bensimon","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"e61177","key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061177","article-title":"Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis.","volume":"8","author":"Berry","year":"2013","journal-title":"PLoS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0003-2697(87)90483-0","article-title":"The creatine phosphate energy shuttle-The molecular asymmetry of a \u201cpool.\u201d.","volume":"161","author":"Bessman","year":"1987","journal-title":"Anal. Biochem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/scd.2006.15.141","article-title":"Human mesenchymal stem cells express neural genes, suggesting a neural predisposition.","volume":"15","author":"Blondheim","year":"2006","journal-title":"Stem Cells Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1212\/WNL.51.2.583","article-title":"A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS\/IGF-I Study Group.","volume":"51","author":"Borasio","year":"1998","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis.","volume":"322","author":"Bordet","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/21678421.2014.943672","article-title":"A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.","volume":"15","author":"Bozik","year":"2014","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.11138\/FNeur\/2016.31.1.007","article-title":"Amyotrophic lateral sclerosis and environmental factors.","volume":"31","author":"Bozzoni","year":"2016","journal-title":"Funct. Neurol."},{"issue":"971","key":"B19","article-title":"A phase I\/II study of recombinant brain-derived neurotrophic in patients with ALS.","volume":"38","author":"Bradley","year":"1995","journal-title":"Ann. Neurol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0026-895X(24)26436-1","article-title":"Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer.","volume":"57","author":"Carlile","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"B21","first-page":"744","article-title":"Deux cas d\u2019atrophie musculaire progressive: avec lesions de la substance grise et des faisceaux ant\u00e9rolat\u00e9raux de la moelle \u00e9pini\u00e9re.","volume":"2","author":"Charcot","year":"1869","journal-title":"Arch. Physiol. Norm. Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.drudis.2016.02.002","article-title":"A look into the future of ALS research.","volume":"21","author":"Clerc","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/nm.2579","article-title":"The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.","volume":"17","author":"Cudkowicz","year":"2011","journal-title":"Nat. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis.","volume":"60","author":"Cudkowicz","year":"2006","journal-title":"Ann. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","article-title":"Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.","volume":"12","author":"Cudkowicz","year":"2013","journal-title":"Lancet Neurol."},{"key":"B26","author":"Cudkowicz","year":"2013","journal-title":"STAGE 3 Clinical Trial of Ceftriaxone in Subjects with ALS (S36.001)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/17482968.2010.498521","article-title":"A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis.","volume":"11","author":"de Carvalho","year":"2010","journal-title":"Amyotroph. Lateral Scler."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1517\/17460441.2015.1067197","article-title":"A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.","volume":"10","author":"DeLoach","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"B29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/sj.bjp.0701885","article-title":"The effect of the nonpeptide neurotrophic compound SR57746A on the progression of the disease state of the pmn mouse.","volume":"124","author":"Duong","year":"1998","journal-title":"Br. J. Pharmacol."},{"issue":"e37885","key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037885","article-title":"A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.","volume":"7","author":"Dupuis","year":"2012","journal-title":"PLoS ONE"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1212\/01.wnl.0000187070.35365.d7","article-title":"Tolerance of high-dose (3,000 mg\/day) coenzyme Q10 in ALS.","volume":"65","author":"Ferrante","year":"2005","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1073\/pnas.0708022105","article-title":"Lithium delays progression of amyotrophic lateral sclerosis.","volume":"105","author":"Fornai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/01.wnl.0000204235.81272.e2","article-title":"Randomized controlled phase II trial of glatiramer acetate in ALS.","volume":"66","author":"Gordon","year":"2006","journal-title":"Neurology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1212\/01.WNL.0000125321.92112.7E","article-title":"Placebo-controlled phase I\/II studies of minocycline in amyotrophic lateral sclerosis.","volume":"62","author":"Gordon","year":"2004","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1755-5949.2008.00048.x","article-title":"KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.","volume":"14","author":"Gribkoff","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"A randomized sequential trial of creatine in amyotrophic lateral sclerosis.","volume":"53","author":"Groeneveld","year":"2003","journal-title":"Ann. Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S0022-510X(97)00247-5","article-title":"The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies.","volume":"152(Suppl. 1)","author":"Gurney","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"issue":"32","key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2010.00032","article-title":"Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: Where do we stand?","volume":"4","author":"Henriques","year":"2010","journal-title":"Front. Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nrneurol.2016.111","article-title":"Supportive and symptomatic management of amyotrophic lateral sclerosis.","volume":"12","author":"Hobson","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/978-1-60761-898-0_27","article-title":"Animal models of amyotrophic lateral sclerosis.","volume":"36","author":"Islam","year":"2014","journal-title":"Genes Genomes"},{"key":"B43","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ncl.2015.07.010","article-title":"Symptom management and end-of-life care in amyotrophic lateral sclerosis.","volume":"33","author":"Jackson","year":"2015","journal-title":"Neurol. Clin."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1212\/WNL.52.7.1427","article-title":"A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF study group (phase III).","volume":"52","author":"Kasarskis","year":"1999","journal-title":"Neurology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.21743","article-title":"Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Ann. Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis.","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/6568","article-title":"Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.","volume":"5","author":"Klivenyi","year":"1999","journal-title":"Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00210-014-1061-6","article-title":"Neuroprotective effect of masitinib in rats with postischemic stroke.","volume":"388","author":"Kocic","year":"2015","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14660820410018973","article-title":"Xaliproden in amyotrophic lateral sclerosis: early clinical trials.","volume":"5","author":"Lacomblez","year":"2004","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II.","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.49.6.1621","article-title":"Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS\/IGF-I Study Group.","volume":"49","author":"Lai","year":"1997","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/17482960902995246","article-title":"Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.","volume":"10","author":"Lauria","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"B53","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/jnnp-2014-308996","article-title":"Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.","volume":"86","author":"Lauria","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ene.12344","article-title":"A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.","volume":"21","author":"Lenglet","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"24438","DOI":"10.3390\/ijms141224438","article-title":"Oxidative stress and neurodegenerative disorders.","volume":"14","author":"Li","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw061","article-title":"Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.","author":"Marin","year":"2016","journal-title":"Int. J. Epidemiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"key":"B58","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/17482960902803432","article-title":"Glatiramer acetate has no impact on disease progression in ALS at 40 mg\/day: a double-blind, randomized, multicentre, placebo-controlled trial.","volume":"10","author":"Meininger","year":"2009","journal-title":"Amyotroph. Lateral Scler."},{"key":"B59","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","article-title":"Phase II\/III randomized trial of TCH346 in patients with ALS.","volume":"69","author":"Miller","year":"2007a","journal-title":"Neurology"},{"issue":"241","key":"B60","article-title":"Safety, tolerability and pharmacokinetics of recombinant human ciliary neurotrophic factor (rhCNTF) in patients with amyotrophic lateral sclerosis (ALS).","volume":"34","author":"Miller","year":"1993","journal-title":"Ann. Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/14651858.CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND).","volume":"822","author":"Miller","year":"2007b","journal-title":"Cochrane Database Syst. Rev."},{"issue":"e100","key":"B62","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000100","article-title":"Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.","volume":"2","author":"Miller","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.410390215","article-title":"A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.","volume":"39","author":"Miller","year":"1996","journal-title":"Ann. Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/21678421.2014.951940","article-title":"NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study.","volume":"15","author":"Miller","year":"2014","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","article-title":"Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved?","volume":"13","author":"Mitsumoto","year":"2014","journal-title":"Lancet Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1474-4422(13)70037-1","article-title":"Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.","volume":"12","author":"Morrison","year":"2013","journal-title":"Lancet Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-015-9337-5","article-title":"Oxidative stress in neurodegenerative diseases.","volume":"53","author":"Niedzielska","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"B68","article-title":"\u201cSustained efficacy for up to 12 months in an active extension of a phase III study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS) (P3.190),\u201d in","author":"Palumbo","year":"2016","journal-title":"Poster Presented at: AAN 2016 Annual Meeting"},{"key":"B69","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.","volume":"11","author":"Pascuzzi","year":"2010","journal-title":"Amyotroph. Lateral Scler."},{"issue":"CD005225","key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005225.pub3","article-title":"Creatine for amyotrophic lateral sclerosis\/motor neuron disease.","volume":"12","author":"Pastula","year":"2012","journal-title":"Cochrane database Syst. Rev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/507423a","article-title":"Preclinical research: make mouse studies work.","volume":"507","author":"Perrin","year":"2014","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.21620","article-title":"Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.","volume":"66","author":"Piepers","year":"2009","journal-title":"Ann. Neurol."},{"issue":"16","key":"B73","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt75","article-title":"Masitinib as an adjunct therapy for mild-to-moderate Alzheimer\u2019s disease: a randomised, placebo-controlled phase 2 trial.","volume":"3","author":"Piette","year":"2011","journal-title":"Alzheimers Res. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10072-005-0474-x","article-title":"Minocycline in amyotrophic lateral sclerosis: a pilot study.","volume":"26","author":"Pontieri","year":"2005","journal-title":"Neurol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-016-8091-6","article-title":"Recent advances in amyotrophic lateral sclerosis.","volume":"263","author":"Riva","year":"2016","journal-title":"J. Neurol."},{"key":"B76","article-title":"\u201cCreatine monohydrate in amyotrophic lateral sclerosis: preliminary results,\u201d in Proceedings of the","author":"Rosenfeld","year":"2001","journal-title":"American Academy of Neurology Annual Meeting"},{"key":"B77","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/17482960802028890","article-title":"Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.","volume":"9","author":"Rosenfeld","year":"2008","journal-title":"Amyotroph. Lateral Scler."},{"key":"B78","first-page":"7","article-title":"Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.","volume":"68","author":"Rothstein","year":"1995","journal-title":"Adv. Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature03180","article-title":"Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/brain\/awt097","article-title":"Is SOD1 loss of function involved in amyotrophic lateral sclerosis?","volume":"136","author":"Saccon","year":"2013","journal-title":"Brain"},{"key":"B81","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.bjp.0703633","article-title":"An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease.","volume":"131","author":"Sagot","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"B82","article-title":"A long-term safety and efficacy extension study of patients diagnosed with amyotrophic lateral sclerosis (ALS) and treated with edaravone (MCI-186) (P3.192).","volume":"86(Suppl. P3.192)","author":"Sakata","year":"2016","journal-title":"Neurology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/17482968.2012.684214","article-title":"Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis.","volume":"13","author":"Shefner","year":"2012","journal-title":"Amyotroph. Lateral Scler."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"A clinical trial of creatine in ALS.","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3109\/21678421.2013.822517","article-title":"A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.","volume":"14","author":"Shefner","year":"2013a","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"B86","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3109\/21678421.2013.817587","article-title":"The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS.","volume":"14","author":"Shefner","year":"2013b","journal-title":"Amyotroph. Lateral Scler. Front. Degener"},{"key":"B87","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3109\/21678421.2016.1148169","article-title":"A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.","volume":"17","author":"Shefner","year":"2016","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","article-title":"Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.","volume":"71","author":"Sorenson","year":"2008","journal-title":"Neurology"},{"key":"B89","article-title":"A 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS) (P3.189).","volume":"86(Suppl. P3.189)","author":"Tanaka","year":"2016a","journal-title":"Neurology"},{"key":"B90","article-title":"A double-blind, parallel-group, placebo-controlled, 24-week, exploratory study of edaravone (MCI-186) for the treatment of advanced amyotrophic lateral sclerosis (ALS) (P3.191).","volume":"86(Suppl. P3.191)","author":"Tanaka","year":"2016b","journal-title":"Neurology"},{"key":"B91","author":"Teva","year":"2010","journal-title":"News Release."},{"issue":"59","key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-016-0658-1","article-title":"ALS: recent developments from genetics studies.","volume":"16","author":"Therrien","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.expneurol.2014.02.021","article-title":"The past, present and future of stem cell clinical trials for ALS.","volume":"262","author":"Thomsen","year":"2014","journal-title":"Exp. Neurol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/1531-8249(199907)46:1129::AID-ANA213.0.CO;2-Y","article-title":"Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis.","volume":"46","author":"Tohgi","year":"1999","journal-title":"Ann. Neurol."},{"issue":"177","key":"B95","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis.","volume":"13","author":"Trias","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"36","key":"B96","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-36","article-title":"Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.","volume":"12","author":"Vermersch","year":"2012","journal-title":"BMC Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/jnnp-2011-302021","article-title":"Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.","volume":"83","author":"Verstraete","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/j.1460-9568.2005.04431.x","article-title":"Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model.","volume":"22","author":"Wang","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"B99","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0022-3565(25)38652-0","article-title":"Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions.","volume":"268","author":"Watanabe","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/17482960600881870","article-title":"Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).","volume":"7","author":"Yoshino","year":"2006","journal-title":"Amyotroph. Lateral Scler."},{"key":"B101","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s11481-013-9489-x","article-title":"Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis.","volume":"8","author":"Zhao","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pneurobio.2016.05.004","article-title":"ALS: a bucket of genes, environment, metabolism and unknown ingredients.","volume":"142","author":"Zufir\u00eda","year":"2016","journal-title":"Prog. Neurobiol."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fnagi.2017.00068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T11:26:06Z","timestamp":1750159566000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fnagi.2017.00068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":102,"URL":"https:\/\/doi.org\/10.3389\/fnagi.2017.00068","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}